258 related articles for article (PubMed ID: 19711464)
1. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
Bradley D; Rathkopf D; Dunn R; Stadler WM; Liu G; Smith DC; Pili R; Zwiebel J; Scher H; Hussain M
Cancer; 2009 Dec; 115(23):5541-9. PubMed ID: 19711464
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of vorinostat in advanced melanoma.
Haas NB; Quirt I; Hotte S; McWhirter E; Polintan R; Litwin S; Adams PD; McBryan T; Wang L; Martin LP; vonMehren M; Alpaugh RK; Zweibel J; Oza A
Invest New Drugs; 2014 Jun; 32(3):526-34. PubMed ID: 24464266
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
Rathkopf DE; Picus J; Hussain A; Ellard S; Chi KN; Nydam T; Allen-Freda E; Mishra KK; Porro MG; Scher HI; Wilding G
Cancer Chemother Pharmacol; 2013 Sep; 72(3):537-44. PubMed ID: 23820963
[TBL] [Abstract][Full Text] [Related]
7. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH
J Clin Endocrinol Metab; 2009 Jan; 94(1):164-70. PubMed ID: 18854394
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
Schneider BJ; Kalemkerian GP; Bradley D; Smith DC; Egorin MJ; Daignault S; Dunn R; Hussain M
Invest New Drugs; 2012 Feb; 30(1):249-57. PubMed ID: 20686817
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
Alva A; Slovin S; Daignault S; Carducci M; Dipaola R; Pienta K; Agus D; Cooney K; Chen A; Smith DC; Hussain M
Invest New Drugs; 2012 Apr; 30(2):749-57. PubMed ID: 21049281
[TBL] [Abstract][Full Text] [Related]
10. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
[TBL] [Abstract][Full Text] [Related]
11. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
Munster PN; Thurn KT; Thomas S; Raha P; Lacevic M; Miller A; Melisko M; Ismail-Khan R; Rugo H; Moasser M; Minton SE
Br J Cancer; 2011 Jun; 104(12):1828-35. PubMed ID: 21559012
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
Luu TH; Morgan RJ; Leong L; Lim D; McNamara M; Portnow J; Frankel P; Smith DD; Doroshow JH; Wong C; Aparicio A; Gandara DR; Somlo G
Clin Cancer Res; 2008 Nov; 14(21):7138-42. PubMed ID: 18981013
[TBL] [Abstract][Full Text] [Related]
14. Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
Yoo C; Ryu MH; Na YS; Ryoo BY; Lee CW; Kang YK
Br J Cancer; 2016 May; 114(11):1185-90. PubMed ID: 27172248
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
Traynor AM; Dubey S; Eickhoff JC; Kolesar JM; Schell K; Huie MS; Groteluschen DL; Marcotte SM; Hallahan CM; Weeks HR; Wilding G; Espinoza-Delgado I; Schiller JH
J Thorac Oncol; 2009 Apr; 4(4):522-6. PubMed ID: 19347984
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Quinn DI; Tsao-Wei DD; Twardowski P; Aparicio AM; Frankel P; Chatta G; Wright JJ; Groshen SG; Khoo S; Lenz HJ; Lara PN; Gandara DR; Newman E
Invest New Drugs; 2021 Jun; 39(3):812-820. PubMed ID: 33409898
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
[TBL] [Abstract][Full Text] [Related]
18. Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO).
Schmitt T; Mayer-Steinacker R; Mayer F; Grünwald V; Schütte J; Hartmann JT; Kasper B; Hüsing J; Hajda J; Ottawa G; Mechtersheimer G; Mikus G; Burhenne J; Lehmann L; Heilig CE; Ho AD; Egerer G
Eur J Cancer; 2016 Sep; 64():74-82. PubMed ID: 27367154
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Patel S; Hurez V; Nawrocki ST; Goros M; Michalek J; Sarantopoulos J; Curiel T; Mahalingam D
Oncotarget; 2016 Sep; 7(37):59087-59097. PubMed ID: 27463016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
